<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672423</url>
  </required_header>
  <id_info>
    <org_study_id>16169</org_study_id>
    <secondary_id>I3Y-MC-JPCC</secondary_id>
    <nct_id>NCT02672423</nct_id>
  </id_info>
  <brief_title>A Study of Abemaciclib in Healthy Participants</brief_title>
  <official_title>A Bioequivalence Study Comparing Abemaciclib Capsule and Tablet Formulations and Effect of Food on Abemaciclib Tablet Pharmacokinetics in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure how much abemaciclib gets into the blood stream and
      how long it takes the body to get rid of it when given as capsules versus a tablet(s). The
      effect of a high fat meal on the tablet formulation will also be evaluated. In addition, the
      tolerability of abemaciclib tablet and capsule formulations will be evaluated. Information
      about any side effects that may occur will also be collected.

      This study has 3 parts. Parts A and C will last about 44 days including follow-up. Part B
      will last about 60 days including follow-up. Screening may occur up to 28 days before the
      first dose of study drug. Participants are only allowed to enroll in one part.

      This study is for research purposes only and is not intended to treat any medical condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])</measure>
    <time_frame>Parts A and C Periods 1 and 2; Part B Periods 1, 2, 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 96, 120,144,168 and 192 hours postdose</time_frame>
    <description>Area under the concentration versus time curve from zero to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax)</measure>
    <time_frame>Parts A and C Periods 1 and 2; Part B Periods 1, 2, 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 96, 120,144,168 and 192 hours postdose</time_frame>
    <description>Maximum observed drug concentration.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Abemaciclib Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abemaciclib Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abemaciclib Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib Capsules (Reference Formulation)</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib Part A</arm_group_label>
    <arm_group_label>Abemaciclib Part B</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib Tablet (Test Formulation)</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib Part A</arm_group_label>
    <arm_group_label>Abemaciclib Part B</arm_group_label>
    <arm_group_label>Abemaciclib Part C</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy surgically sterile or postmenopausal females and sterile males

          -  Have a body mass index (BMI) 18 to 32 kilograms per square meter (kg/m²)

        Exclusion Criteria:

          -  Have known allergies to abemaciclib, related compounds, or any components of the
             formulation

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human
             HIV antibodies

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Daytona Beach Clinical Research Unit</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evansville Clinical Research Unit</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <results_first_submitted>October 27, 2017</results_first_submitted>
  <results_first_submitted_qc>October 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2018</results_first_posted>
  <last_update_submitted>December 13, 2018</last_update_submitted>
  <last_update_submitted_qc>December 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A 2- and 3-period crossover study conducted in 3 parts, with Part A followed by Parts B and C. Participants received single oral doses of abemaciclib on 2 separate occasions in Parts A and C and on 3 separate occasions in Part B.There was a washout interval of at least 16 days between periods.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: Abemaciclib (R,T150 )</title>
          <description>Reference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.</description>
        </group>
        <group group_id="P2">
          <title>Part A: Abemaciclib (T150,R)</title>
          <description>T150 = 150 mg abemaciclib tablet, R = 3 x 50 mg abemaciclib capsules administered orally on Day 1 in each of 2 periods.</description>
        </group>
        <group group_id="P3">
          <title>Part B: Abemaciclib (R,T150,T50 )</title>
          <description>R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.</description>
        </group>
        <group group_id="P4">
          <title>Part B: Abemaciclib (T150,T50,R)</title>
          <description>T150 = 150 mg abemaciclib tablet, R = 3 x 50 mg abemaciclib capsules, T50 = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.</description>
        </group>
        <group group_id="P5">
          <title>Part B: Abemaciclib (T50,R,T150)</title>
          <description>T50 = 3 x 50 mg abemaciclib tablets, R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet administered orally on Day 1 in each of 3 periods.</description>
        </group>
        <group group_id="P6">
          <title>Part B: Abemaciclib (R,T50,T150)</title>
          <description>R = 3 x 50 mg abemaciclib capsules, T50 = 3 x 50 mg abemaciclib tablets, T150 = 150 mg abemaciclib tablet administered orally on Day 1 in each of 3 periods.</description>
        </group>
        <group group_id="P7">
          <title>Part B: Abemaciclib (T150,R,T50)</title>
          <description>T150 = 150 mg abemaciclib tablet, R = 3 x 50 mg abemaciclib capsules, T50 = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.</description>
        </group>
        <group group_id="P8">
          <title>Part B: Abemaciclib (T50,T150,R)</title>
          <description>T50 = 3 x 50 mg abemaciclib tablets, T150 = 150 mg abemaciclib tablet, R = 3 x 50 mg abemaciclib capsules administered orally on Day 1 in each of 3 periods.</description>
        </group>
        <group group_id="P9">
          <title>Part C: Abemaciclib (T150 Fed, T150 Fasted)</title>
          <description>T150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.</description>
        </group>
        <group group_id="P10">
          <title>Part C: Abemaciclib (T150 Fasted, T150 Fed)</title>
          <description>T150 Fasted and T150 Fed = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Part A was a 2-period study design.</participants>
                <participants group_id="P2" count="0">Part A was a 2-period study design.</participants>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="0">Part C was a 2-period study design.</participants>
                <participants group_id="P10" count="0">Part C was a 2-period study design.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A: Abemaciclib</title>
          <description>Reference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.</description>
        </group>
        <group group_id="B2">
          <title>Part B Abemaciclib</title>
          <description>R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.</description>
        </group>
        <group group_id="B3">
          <title>Part C Abemaciclib</title>
          <description>T150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="127"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" spread="16.9"/>
                    <measurement group_id="B2" value="51.8" spread="11.6"/>
                    <measurement group_id="B3" value="55.5" spread="10.6"/>
                    <measurement group_id="B4" value="52.7" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])</title>
        <description>Area under the concentration versus time curve from zero to infinity.</description>
        <time_frame>Parts A and C Periods 1 and 2; Part B Periods 1, 2, 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 96, 120,144,168 and 192 hours postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 150 mg Abemaciclib (T150)</title>
            <description>150 mg abemaciclib tablet (test formulation[T150]) administered orally on Day 1 of 1 period.</description>
          </group>
          <group group_id="O2">
            <title>Part A: 3 x 50 mg Abemaciclib (R)</title>
            <description>3 x 50 mg abemaciclib capsules (reference formulation[R]) administered orally on Day 1 of 1 period.</description>
          </group>
          <group group_id="O3">
            <title>Part B: 150 mg Abemaciclib (T150)</title>
            <description>150 mg abemaciclib tablet (test formulation[T150]) administered orally on Day 1 of 1 period.</description>
          </group>
          <group group_id="O4">
            <title>Part B: 3 x 50 mg Abemaciclib (T50)</title>
            <description>3 x 50 mg abemaciclib tablets (T50) administered orally on Day 1 of 1 period.</description>
          </group>
          <group group_id="O5">
            <title>Part B: 3 x 50 mg Abemaciclib (R)</title>
            <description>3 x 50 mg abemaciclib capsules (reference formulation[R]) administered orally on Day 1 of 1 period.</description>
          </group>
          <group group_id="O6">
            <title>Part C: 150 mg Abemaciclib (Fed)</title>
            <description>150 mg abemaciclib tablet (test formulation [T150]) with a meal administered orally on Day 1 of 1 period.</description>
          </group>
          <group group_id="O7">
            <title>Part C: 150 mg Abemaciclib (Fasted)</title>
            <description>150 mg abemaciclib tablet (test formulation[T150]) without a meal administered orally on Day 1 of 1 period.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])</title>
          <description>Area under the concentration versus time curve from zero to infinity.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>Nanograms*hour/milliliter (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="84"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3080" spread="57"/>
                    <measurement group_id="O2" value="2880" spread="56"/>
                    <measurement group_id="O3" value="3110" spread="55"/>
                    <measurement group_id="O4" value="3120" spread="52"/>
                    <measurement group_id="O5" value="3130" spread="59"/>
                    <measurement group_id="O6" value="4170" spread="49"/>
                    <measurement group_id="O7" value="3590" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: Maximum Observed Drug Concentration (Cmax)</title>
        <description>Maximum observed drug concentration.</description>
        <time_frame>Parts A and C Periods 1 and 2; Part B Periods 1, 2, 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 96, 120,144,168 and 192 hours postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 150 mg Abemaciclib (T150)</title>
            <description>150 mg abemaciclib tablet (test formulation[T150]) administered orally on Day 1 of 1 period.</description>
          </group>
          <group group_id="O2">
            <title>Part A: 3 x 50 mg Abemaciclib (R)</title>
            <description>3 x 50 mg abemaciclib capsules (reference formulation [R]) administered orally on Day 1 of 1 period.</description>
          </group>
          <group group_id="O3">
            <title>Part B:150 mg Abemaciclib (T150)</title>
            <description>150 mg abemaciclib tablet (test formulation [T150]) administered orally on Day 1 of 1 period.</description>
          </group>
          <group group_id="O4">
            <title>Part B: 3 x 50 mg Abemaciclib (T50)</title>
            <description>3 x 50 mg abemaciclib tablets (T50) administered orally on Day 1 of 1 period.</description>
          </group>
          <group group_id="O5">
            <title>Part B: 3 x 50 mg Abemaciclib (R)</title>
            <description>3 x 50 mg abemaciclib capsules (reference formulation [R]) administered orally on Day 1 of 1 period.</description>
          </group>
          <group group_id="O6">
            <title>Part C:150 mg Abemaciclib (Fed)</title>
            <description>150 mg abemaciclib tablet (test formulation[T150]) with a meal administered orally on Day 1 of 1 period.</description>
          </group>
          <group group_id="O7">
            <title>Part C:150 mg Abemaciclib (Fasted)</title>
            <description>150 mg abemaciclib tablet (test formulation[T150]) without a meal administered orally on Day 1 of 1 period.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Maximum Observed Drug Concentration (Cmax)</title>
          <description>Maximum observed drug concentration.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="84"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" spread="52"/>
                    <measurement group_id="O2" value="101" spread="56"/>
                    <measurement group_id="O3" value="95.2" spread="48"/>
                    <measurement group_id="O4" value="97.7" spread="50"/>
                    <measurement group_id="O5" value="95.8" spread="51"/>
                    <measurement group_id="O6" value="130" spread="44"/>
                    <measurement group_id="O7" value="99.6" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All randomized participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A: 3 x 50 mg (R)</title>
          <description>3 x 50 milligrams (mg) abemaciclib capsules (reference formulation [R]) administered orally on Day 1 of 1 period.</description>
        </group>
        <group group_id="E2">
          <title>Part A: 1 x 150 mg (T150)</title>
          <description>150 mg abemaciclib tablet (test formulation[T150]) administered orally on Day 1 of 1 period.</description>
        </group>
        <group group_id="E3">
          <title>Part B: 3 x 50 mg (R)</title>
          <description>3 x 50 milligrams (mg) abemaciclib capsules (reference formulation[R]) administered orally on Day 1 of 1 period.</description>
        </group>
        <group group_id="E4">
          <title>Part B 1 x 150 mg (T150)</title>
          <description>150 mg abemaciclib tablet (test formulation[T150]) administered orally on Day 1 of 1 period.</description>
        </group>
        <group group_id="E5">
          <title>Part B 3 x 50 mg (T50)</title>
          <description>3 x 50 mg abemaciclib tablets (test formulation[T50]) administered orally on Day 1 of 1 period.</description>
        </group>
        <group group_id="E6">
          <title>Part C: (T150 Fed, T150 Fasted)</title>
          <description>150 mg abemaciclib tablet (test formulation [T150]) with a meal and then without a meal administered orally on Day 1 of 1 period..</description>
        </group>
        <group group_id="E7">
          <title>Part C: (T150 Fasted, T150 Fed)</title>
          <description>150 mg abemaciclib tablet (test formulation [T150]) without a meal and then with a meal administered orally on Day 1 of 1 period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="88"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="88"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="88"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

